Aside from these unresolved questions, successful clinical trials of both IL-1 and IL-6 blockade leading to their regulatory approval for treatment of sJIA have undoubtedly transformed clinical outcomes by ameliorating systemic inflammation, preventing destructive arthritis, and reducing glucocorticoid toxicity (8, 10). Here, IL6 is linked to systemic-onset juvenile idiopathic arthritis.